

## Rhythm Biosciences Executes Distribution Agreement for geneType<sup>™</sup> for Southeast Asian Market

### Highlights

- ✓ Rhythm Biosciences Limited (ASX: RHY) has executed a Supply and Distribution Agreement with Digistain Limited (UK), a specialist international distributor of cancer diagnostic products with established commercial networks across Southeast Asia.
- ✓ The Agreement grants Digistain the right to market and distribute the Company's geneType<sup>™</sup> genetic test portfolio, commencing in the Philippines as an initial launch market, with the potential to include additional Southeast Asian markets as agreed by the parties.
- ✓ The Agreement has a 12-month initial term commencing 3rd March 2026, with renewal provisions supporting scalable regional expansion.
- ✓ The Agreement includes a structured pricing framework providing Rhythm with clear revenue visibility.
- ✓ This Agreement marks Rhythm's first formal commercial entry into Southeast Asia and is consistent with the Company's strategy to drive international adoption of its geneType<sup>™</sup> platform across high-growth markets.

---

**Melbourne, Australia, 4th March 2026:** Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX: RHY), a transformative, predictive cancer diagnostics technology company is pleased to announce it has executed a Supply Agreement (the "Agreement") with Digistain Limited (Company Number: 12329264), a UK-incorporated cancer diagnostics company with an active international distribution footprint including in South East Asia, for the supply of the Company's geneType<sup>™</sup> genetic test portfolio.

### Background and Strategic Context

Rhythm Biosciences Ltd  
ACN 619 459 335  
ASX: RHY

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**Directors**

Gavin Fox-Smith  
Sue MacLeman  
David Atkins

Non-Executive Chairman  
Non-Executive Director  
CEO & Managing Director

[www.rhythmbio.com](http://www.rhythmbio.com)

T +61 3 8256 2880  
E [info@rhythmbio.com](mailto:info@rhythmbio.com)

Rhythm's geneType™ platform, acquired as part of the Company's dual-platform strategy for early cancer detection, provides clinically validated genetic risk assessment across nine tests spanning cancer predisposition and cardio-metabolic risk. The platform is designed for broad international applicability, with testing conducted at the Company's NATA-accredited laboratory and laboratory partner, AGRF in Melbourne.

Southeast Asia represents a significant and underserved addressable market for genetic risk testing. The region's large population base, increasing healthcare expenditure, improving access to private healthcare, and relatively low current penetration of advanced genetic diagnostics create a compelling opportunity for an internationally validated and cost-effective testing platform such as geneType™.

Digistain Limited, headquartered in Newport Pagnell, England, distributes cancer diagnostic products across multiple international markets and brings to this partnership established commercial infrastructure and sub-distribution networks within Southeast Asia, including through its existing relationship with Precision Healthcare PTE. This positions Digistain as an effective commercialisation partner for Rhythm's regional expansion ambitions.

This Agreement represents Rhythm's first contracted commercial entry into Southeast Asia and establishes an initial revenue-generating distribution channel for geneType™ in the region. The inclusion of minimum volume commitments and per-test pricing provides a baseline level of expected activity during the initial term, with potential upside as additional markets are activated through Digistain's distribution network.

### **Agreement Details**

Under the terms of the Agreement, Rhythm will supply the geneType™ test portfolio, including saliva collection devices, laboratory processing and clinical reporting to Digistain for distribution within the Territory. The Territory is defined as the Philippines and other markets as agreed by the parties, reflecting the parties shared intention to use the initial launch market as a foundation from which to expand Digistain's geneType™ commercial operations across the Southeast Asian region.

Key commercial terms of the Agreement include:

- Initial term of 12 months from 3rd March 2026, with renewal by mutual agreement.
- An agreed per-test transfer price for the initial Territory.
- A volume commitment per month, providing Rhythm with a baseline commercial floor during market establishment.
- A supply and reporting turnaround of 6 weeks from receipt of patient samples, consistent with Rhythm's existing service standards.
- Non-exclusive supply arrangements, allowing Rhythm to engage additional distribution partners across the broader region as the opportunity develops.

The Agreement is governed by the laws of Victoria, Australia and provides for structured dispute resolution including escalation, mediation and arbitration provisions, consistent with Rhythm's standard commercial contracting approach.

#### **Financial Impact**

The Agreement does not include upfront payments or capital commitments from either party. Revenue to Rhythm will be generated on a per-test basis as samples are processed and reported, invoiced monthly with 30-day payment terms.

The Company is unable to provide specific revenue guidance at this time given the early-stage nature of the initial Territory launch and the inherent uncertainty in forecasting adoption rates in a new market. The commercial significance of this Agreement lies primarily in its role as a strategic platform for Southeast Asian market entry and its potential to support growth in geneType<sup>™</sup> test volumes as Digistain's regional distribution network is activated.

#### **Management Comment**

David Atkins, Managing Director and CEO of Rhythm Biosciences, commented: "This agreement represents a meaningful step in translating our geneType<sup>™</sup> platform into commercial test volumes. Southeast Asia is a region where we see genuine long-term opportunity for genetic risk testing and partnering with an established international distributor such as Digistain gives us a structured and

capital-efficient pathway into these markets. We see this as the beginning of a scalable regional opportunity.”

Dr Hemmel Amrania, CEO of Digistain Limited, commented: “We are excited to be adding geneType<sup>™</sup> to our cancer diagnostics portfolio for Southeast Asia. Genetic risk testing is an area of growing clinical and consumer demand across the region and the geneType<sup>™</sup> platform’s breadth of validated tests and digital delivery infrastructure makes it ideally suited for the markets we serve. We look forward to introducing geneType<sup>™</sup> to clinicians and patients and building a strong commercial relationship with the Rhythm team.”

### **Next Steps**

Rhythm and Digistain will progress the operational onboarding phase of the Agreement, including training of Digistain personnel, finalisation of sample logistics protocols for South-East Asian markets and co-development of marketing materials.

The Company will provide further updates as commercial activity commences and as additional markets within the Territory are activated.

- ENDS -

**This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.**

**For further information contact us via [investors@rhythmbio.com](mailto:investors@rhythmbio.com).**

#### **About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer, and saving lives. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions. The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

#### **About ColoSTAT<sup>®</sup>**

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer can be curable. The ColoSTAT<sup>®</sup> Test is Rhythm Bioscience’s simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. It is intended for individuals with symptoms associated with Colorectal Cancer (CRC). The ColoSTAT<sup>®</sup> Test is based on research from Australia’s CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

#### **About geneType<sup>™</sup>**

geneType<sup>™</sup> is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer, and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit [www.genetype.com](http://www.genetype.com).

**About Digistain Limited**

Digistain Limited is a UK-incorporated cancer diagnostics company headquartered in Newport Pagnell, England. Digistain distributes cancer diagnostic products across multiple international markets including Southeast Asia. The company was founded by Dr Hemmel Amrania, CEO, and has established commercial distribution networks and partnerships across Asia, Scandinavia and Latin America. Digistain brings an existing sub-distribution infrastructure to the Southeast Asian market, including an established relationship with Precision Healthcare PTE.

For personal use only